Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma?

Journal of Nuclear Medicine

Volumn 45, Issue 8, 2004, Pages 1323-1327

  Fuster, David ^a   Chiang, Stephen ^a   Johnson, Germaine ^a   Schuchter, Lynn M ^a   Zhuang, Hongming ^a   Alavi, Abass ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

18F FDG; Diagnosis; Melanoma; Metastases; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ABDOMINAL CANCER; ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RESEARCH; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ABDOMINAL TUMOR; BONE TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; LIVER TUMOR; LUNG TUMOR; MELANOMA; METASTASIS; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; TUMOR RECURRENCE; VALIDATION STUDY;

ABDOMINAL NEOPLASMS; BONE NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 4544295230     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Gershenwald JE, Fischer D, Buzaid AC. Clinical classification and staging. Clin Plast Surg. 2000;27:361-376.
2. Vidal-Sicart S, Pons F, Puig S, et al. Identification of the sentinel lymph node in patients with malignant melanoma: what are the reasons for mistakes? Eur J Nucl Med. 2003;30:362-366.
3. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med. 1993;34:1420-1427.
4. 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer. 1998;82:1664-1671.
5. Wagner JD, Schauwecker D, Hutchins G, Coleman JJ. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol. 1997;64:181-189.
6. 18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol. 1998;16:1770-1776.
7. Acland KM, Healy C, Calonje E, et al. Comparison of positron emission tomography scanning and sentinel lymph node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol. 2001;19:2674-2678.
8. Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G. Positron emission tomography and ultrasonography: a comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol. 1995;132:1394-1398.
9. Mijnhout GS, Hoekstra OS, van Lingen A, et al. How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: the case of lymph node staging in melanoma. J Clin Pathol. 2003;56:283-286.
10. Wagner JD, Schauwecker D, Davidson D, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel lymph node biopsy. J Clin Oncol. 1999;17:1508-1515.
11. Boni R, Boni RA, Steinert H, et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D- glucose. Br J Dermatol. 1995;132:556-562.
12. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res. 1996;6:325-329.
13. Steinert HC, Huch Boni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D- glucose. Radiology. 1995;195:705-709.
14. Steinert HC, Voellmy DR, Trachsel C, et al. Planar coincidence scintigraphy and PET in staging malignant melanoma. J Nucl Med. 1998;39:1892-1897.
15. Eigtved A, Andersson AP, Dahlstrom K, Rabol A, Jensen M. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med. 2000;27:70-75.
16. Holder WD, White RL, Zuger JH, Easton EJ, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg. 1998;227:764-771.
17. Jadvar H, Johnson DL, Segall GM. The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma. Clin Nucl Med. 2000;25:48-51.
18. Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma. Cancer. 2000;89:1019-1025.
19. Krug B, Dietlein M, Groth W, et al. Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma: diagnosing comparison with conventional imaging methods. Acta Radiol. 2000;41:446-452.
20. Paquet P, Henry F, Belhocine T, et al. An appraisal of 18-fluorodeoxyglucose positron emission tomography for melanoma staging. Dermatology. 2000;200:167-169.
21. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol. 2001;19:3635-3648.
22. Kokoska MS, Olson G, Kelemen PR, et al. The use of lymphoscintigraphy and PET in the management of head and neck melanoma. Otolaryngol Head Neck. 2001;125:213-220.
23. Olson JA, Jaques DP, Coit DG, Hwu WJ. Staging work-up and post-treatment surveillance of patients with melanoma. Clin Plast Surg. 2000;27:377-390.
24. Acland KM, O'Doherty MJ, Russell-Jones R. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J Am Acad Dermatol. 2000;42:606-611.
25. 18F-fluorodeoxyglucose positron emission tomography in recurrent melanoma. Nucl Med Commun. 2002;23:475-481.
26. Dalrymple-Hay MJ, Rome PD, Kennedy C, Fulham M, McCaughan BC. Pulmonary metastatic melanoma: the survival benefit associated with positron emission tomography scanning. Eur J Cardiothorac Surg. 2002;21:611-615.
27. Karakousis CP, Velez A, Driscoll BA. Metastasectomy in malignant melanoma. Surgery. 1994;115:295-302.
28. Wong JH, Skinner KA, Kim KA, et al. The role of surgery in the treatment of nonregionally recurrent melanoma. Surgery. 1993;113:389-394.